Literature DB >> 33670346

Whole-Genome Sequencing of Retinoblastoma Reveals the Diversity of Rearrangements Disrupting RB1 and Uncovers a Treatment-Related Mutational Signature.

Helen R Davies1,2, Kevin D Broad3, Zerrin Onadim4, Elizabeth A Price4, Xueqing Zou1,2, Ibrahim Sheriff5, Esin Kotiloğlu Karaa6, Irene Scheimberg6, M Ashwin Reddy5,7, Mandeep S Sagoo3,5,7, Shin-Ichi Ohnuma3, Serena Nik-Zainal1,2.   

Abstract

The development of retinoblastoma is thought to require pathological genetic changes in both alleles of the RB1 gene. However, cases exist where RB1 mutations are undetectable, suggesting alternative pathways to malignancy. We used whole-genome sequencing (WGS) and transcriptomics to investigate the landscape of sporadic retinoblastomas derived from twenty patients, sought RB1 and other driver mutations and investigated mutational signatures. At least one RB1 mutation was identified in all retinoblastomas, including new mutations in addition to those previously identified by clinical screening. Ten tumours carried structural rearrangements involving RB1 ranging from relatively simple to extremely complex rearrangement patterns, including a chromothripsis-like pattern in one tumour. Bilateral tumours obtained from one patient harboured conserved germline but divergent somatic RB1 mutations, indicating independent evolution. Mutational signature analysis showed predominance of signatures associated with cell division, an absence of ultraviolet-related DNA damage and a profound platinum-related mutational signature in a chemotherapy-exposed tumour. Most RB1 mutations are identifiable by clinical screening. However, the increased resolution and ability to detect otherwise elusive rearrangements by WGS have important repercussions on clinical management and advice on recurrence risks.

Entities:  

Keywords:  mutational signature; retinoblastoma; structural rearrangement; whole-genome sequencing

Year:  2021        PMID: 33670346     DOI: 10.3390/cancers13040754

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  7 in total

1.  Aqueous Humor as a Liquid Biopsy for Retinoblastoma: Clear Corneal Paracentesis and Genomic Analysis.

Authors:  Mary E Kim; Liya Xu; Rishvanth K Prabakar; Lishuang Shen; Chen-Ching Peng; Peter Kuhn; Xiaowu Gai; James Hicks; Jesse L Berry
Journal:  J Vis Exp       Date:  2021-09-07       Impact factor: 1.424

Review 2.  Genome maintenance in retinoblastoma: Implications for therapeutic vulnerabilities.

Authors:  Chunsik Lee; Jong Kyong Kim
Journal:  Oncol Lett       Date:  2022-04-29       Impact factor: 3.111

3.  RB1 loss triggers dependence on ESRRG in retinoblastoma.

Authors:  Matthew G Field; Jeffim N Kuznetsoff; Michelle G Zhang; James J Dollar; Michael A Durante; Yoseph Sayegh; Christina L Decatur; Stefan Kurtenbach; Daniel Pelaez; J William Harbour
Journal:  Sci Adv       Date:  2022-08-19       Impact factor: 14.957

4.  PRELP Regulates Cell-Cell Adhesion and EMT and Inhibits Retinoblastoma Progression.

Authors:  Jack Hopkins; Ken Asada; Alex Leung; Vasiliki Papadaki; Hongorzul Davaapil; Matthew Morrison; Tomoko Orita; Ryohei Sekido; Hirofumi Kosuge; M Ashwin Reddy; Kazuhiro Kimura; Akihisa Mitani; Kouhei Tsumoto; Ryuji Hamamoto; Mandeep S Sagoo; Shin-Ichi Ohnuma
Journal:  Cancers (Basel)       Date:  2022-10-08       Impact factor: 6.575

5.  Comprehensive Somatic Copy Number Analysis Using Aqueous Humor Liquid Biopsy for Retinoblastoma.

Authors:  Mary E Kim; Ashley Polski; Liya Xu; Rishvanth K Prabakar; Chen-Ching Peng; Mark W Reid; Rachana Shah; Peter Kuhn; David Cobrinik; James Hicks; Jesse L Berry
Journal:  Cancers (Basel)       Date:  2021-07-03       Impact factor: 6.639

Review 6.  The Impact of Cell-Free DNA Analysis on the Management of Retinoblastoma.

Authors:  Amy Gerrish; Helen Jenkinson; Trevor Cole
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

7.  Inter-eye genomic heterogeneity in bilateral retinoblastoma via aqueous humor liquid biopsy.

Authors:  Elyssa Y Wong; Liya Xu; Lishuang Shen; Mary E Kim; Ashley Polski; Rishvanth K Prabakar; Rachana Shah; Rima Jubran; Jonathan W Kim; Jaclyn A Biegel; Xiaowu Gai; Peter Kuhn; James Hicks; Jesse L Berry
Journal:  NPJ Precis Oncol       Date:  2021-07-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.